The year 2023 marked significant advancements in biopharma, with notable milestones such as the approval of the Alzheimer’s disease drug Leqembi and the first CRISPR-edited therapy.
As we reflect on these pivotal moments and anticipate what 2024 holds, GEN engaged CEOs from three prominent companies—Zevra Therapeutics, Axogen, and Ryght—to share insights on the broader industry landscape and their respective company strategies.
Neil McFarlane of Zevra highlights the company's recent acquisition and its progress towards treating Niemann-Pick disease type C. Karen Zaderej from Axogen discusses the company's growth trajectory and the launch of innovative nerve products.
Simon Arkell of Ryght delves into the company's generative AI platform to enhance biopharma decision-making.
Read the full article here on genengnews.com
About Ryght
Ryght is a privately held healthcare technology company based in Anaheim, California that is developing the next generation of safe and secure generative artificial intelligence (GenAI) solutions for the biopharma industry. The Ryght platform leverages and optimizes multiple large language models (LLMs) and vector databases to ingest real-time data streams and make actionable knowledge directly available to biopharma discovery, clinical, and commercial teams. The platform enables healthcare professionals to rapidly leverage the power of GenAI within compliance of data security standards required by the industry.
Follow the company on 